Dr. Paramdeep S. Baweja, MD
Cardiology (Cardiovascular Disease Physician)
- Medicare participating
At a glance
- Years since graduation
- 28
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 538
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
MO license 2009003004
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Nkc Health North Kansas City, MO
- Truman Medical Center Hospital Hill Kansas City, MO
- University Health Lakewood Medical Center Kansas City, MO
Medical groups
- University Health Physicians (350 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 538
- Services billed
- 1,185
- Patients’ average age
- 65
| Service | Times | Patients |
|---|---|---|
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 820 | 515 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 121 | 119 |
| Heart muscle strain imaging | 111 | 108 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 38 | 36 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 37 | 37 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 37 | 37 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 36 | 36 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 34 | 33 |
| Ultrasound of heart, follow-up | 31 | 30 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 28 | 28 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Brilinta (ticagrelor) Other prescribers in Kansas City, MO | 34 |
| Entresto (sacubitril/valsartan) Other prescribers in Kansas City, MO | 16 |
| Spironolactone Other prescribers in Kansas City, MO | 13 |
| Eliquis (apixaban) Other prescribers in Kansas City, MO | 11 |
| Isosorbide Mononitrate Er (isosorbide mononitrate) Other prescribers in Kansas City, MO | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $112 in total to this clinician.
| Abbott Laboratories | $94.56 |
|---|---|
| Zoll Services LLC (a/k/a Zoll Lifecor Corp) | $17.61 |
| Food and Beverage | $112 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $145 in research payments for these studies, mostly to the institutions running them.
- A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a)…
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.